InflaRx N.V. - Common Stock (NQ:IFRX)

1.720 +0.010 (+0.58%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about InflaRx N.V. - Common Stock

< Previous 1 2 3 4 5 6 Next >

InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026

October 02, 2026

From InflaRx N.V.

Via GlobeNewswire

InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development

October 01, 2026

From InflaRx N.V.

Via GlobeNewswire

InflaRx to Host Virtual Capital Markets Day

September 21, 2026

From InflaRx N.V.

Via GlobeNewswire

InflaRx Announces Participation in September Investor Conferences

August 20, 2026

From InflaRx N.V.

Via GlobeNewswire

InflaRx (NASDAQ:IFRX) Tumbles After Q2 Results Miss Estimates ↗

August 06, 2026

Via Chartmill

IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases ↗

November 10, 2025

Via Stocktwits

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

August 06, 2026

From InflaRx N.V.

Via GlobeNewswire

InflaRx to Report Second Quarter 2026 Results on August 6, 2026

July 30, 2026

From InflaRx N.V.

Via GlobeNewswire

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

June 30, 2026

From InflaRx N.V.

Via GlobeNewswire

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline ↗

May 08, 2026

InflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company...

Via MarketBeat

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

May 08, 2026

From InflaRx N.V.

Via GlobeNewswire

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

May 06, 2026

From InflaRx N.V.

Via GlobeNewswire

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

May 06, 2026

From InflaRx N.V.

Via GlobeNewswire

Friday's session: top gainers and losers ↗

April 17, 2026

Via Chartmill

Get insights into the top gainers and losers of Friday's after-hours session. ↗

November 21, 2025

Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 18, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 18, 2025

Via Benzinga

Is InflaRx NV Gaining or Losing Market Support? ↗

November 14, 2025

Via Benzinga

These stocks have an unusual volume in today's session ↗

November 12, 2025

Volume analysis on 2025-11-12: stocks with an unusual volume in today's session.

Via Chartmill

In today's session, these stocks are experiencing unusual volume. ↗

November 11, 2025

Discover the stocks with unexpected trading volume in today's session on the US markets.

Via Chartmill

Earnings Season: Synergy CHC (NASDAQ: SNYR) FOCUSfactor® Beverage – Eyes $100M+ in 2026 – More Stocks Reporting Inside

November 10, 2025

Via AB Newswire

Topics Artificial Intelligence

Top movers analysis one hour before the close of the markets on 2025-11-10: top gainers and losers in today's session. ↗

November 10, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

These stocks are the most active in today's session ↗

November 10, 2025

Monday's session is buzzing with activity. Check out the stocks that are attracting the most attention and driving market activity!

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 10, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 10, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

November 10, 2025

Via Benzinga

What's going on in today's after hours session ↗

November 07, 2025

The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.

Via Chartmill

Biogen's Immunology Pipeline Has Long-Term Potential: Analyst ↗

October 24, 2025

Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across multiple immune diseases.

Via Benzinga

Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge ↗

September 08, 2025

Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.